Skip to main content
  • Moderna and the Bill & Melinda Gates Foundation Create Global Health Partnership

    “Moderna’s research has considerable potential for the development of an effective prevention intervention for HIV, and potentially other infectious diseases that disproportionately affect the world’s poorest people.”

    Dr. Trevor Mundel, president of Global Health at the Bill & Melinda Gates Foundation

  • AstraZeneca and Moderna Therapeutics Announce New Collaboration to Co-Develop and Co-Commercialize Immuno-Oncology mRNA Therapeutics™

    “We’re pleased to be expanding our relationship with Moderna with this new collaboration, to advance the potential of pioneering messenger RNA technology in developing game-changing new treatments for cancer patients.”

    Dr. Pascal Soriot, CEO of AstraZeneca

  • Moderna Licenses New Vaccine Candidates to Merck

    Ongoing collaboration is yielding rapid progress; first vaccine candidate anticipated to enter clinic in 2016

  • Advancing mRNA therapy for Crigler-Najjar Syndrome Type 1; to enter clinic in 2016

    Undoubtedly, the collaboration with Moderna is one of the most exciting projects in Alexion’s pipeline. After many years of hope about messenger RNA therapeutics, there is belief that Moderna could be on the cusp of developing a ground-breaking treatment using the technology.

    pharmaphorum, following Alexion’s R&D Day, December 10, 2015

  • “We had the opportunity to really get in under the hood. [Moderna] is a company that we’ve talked with and known for quite a long time. So we had the opportunity to look at them very carefully and to look at the data that they’ve produced preclinically, and frankly it’s enormously impressive. The translation to humans, of course, will have its challenges but it’s something that we felt we were in a relatively unique position to pursue and so did they. I have to tell you the nature of those interactions has been extremely positive.”

    Dr. Roger M. Perlmutter, president of Merck Research Laboratories, as quoted in Forbes.

  • Moderna has been selected as a 2015 Top Employer by Science magazine.

  • Moderna is #1 on CNBC’s 2015 Disruptor 50 list. CNBC recognizes Moderna for our disruptive technology and innovative business model.

Our Mission

Deliver on the promise of mRNA science to create a new generation of transformative medicines for patients.